Merck & Co. secured FDA approval for Enflonsia (cesrovimab), a monoclonal antibody preventing respiratory syncytial virus in infants. This approval arrives amidst the unprecedented removal of the CDC’s vaccine advisory committee by HHS Secretary Robert F. Kennedy Jr., casting uncertainty over vaccine policy deliberations. The ACIP’s upcoming meeting will proceed with a reconstituted panel, potentially impacting Enflonsia’s clinical adoption timeline.